Samsung Biologics Partners with LegoChem Biosciences on ADCs

Samsung Biologics announced on Feb. 7, 2024 that it has signed a partnership agreement with LegoChem Biosciences, a biotech company focused on antibody-drug conjugate (ADC) programs, to develop and manufacture an antibody for an ADC candidate.

Under the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services for LegoChem Biosciences’ ADC program for treating solid tumors. LegoChem Biosciences intends to submit an investigational new drug application to FDA in the first half of 2025. According to a company press release, non-clinical data has shown promising efficacy results.

Samsung Biologics is on track to adding ADCs to its pipeline. The company expects to have a new standalone, dedicated ADC facility—currently being constructed—to be operational within 2024.

“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” said John Rim, CEO and president of Samsung Biologics, in the press release. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”

“LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract,” said Yong-Zu Kim, CEO and president of LegoChem Biosciences, in the release.

Source: Samsung Biologics